This Conference is designed by QPs for QPs as an international Expert Forum with focus on sharing information and experience and on discussing the critical areas of the QP’s daily work.
Come and visit us the ILMAC Messe Basel to the Data Integrity session on 20. September 2016, 09:30 – 12:40.
Read more: External Reference
comes compliance services (CCS), a leading GXP consulting service provider, for Pharmaceutical Quality Systems, Data Governance and Integrity, Computer System Validation and Inspection Readiness Programs, today announced that it has acquired more than 100 business customers since the launch of its services in 2009. Pharmaceutical and Medical Device customers rely on the compliance and consultancy services since many years provided by CCS. About 80 % of CCS projects are repeat-business and sales continue to ramp steadily. Continue reading “CCS – 100 – business customers reached in 2016”
- Europe EMA (Q&A GMP) – see below full text
- PIC/S: PI_041_1_Draft_2_Guidance_on_Data_Integrity_2
- WHO – Technical Report 996 – WHO_TRS_996_annex05
- British MHRA (before “Brexit”): July 2016 Draft
- US-FDA: Guidance for Industry: US-FDA Data Integrity
EMA Q&A: Data integrity (NEW August 2016) Continue reading “All Data Integrity Guidances at a glance”
The European Medicines Agency (EMA) has added to the GMP Q&A blog the topic “Data Integrity”. The agency states that the questions should be read in conjunction with Eudralex Volume 4 (GMP guidelines). Find all 23 of the questions and answers via the following link.
PIC/S has published on a draft basis a guidance on Good Practices for Data Management and Integrity in Regulated GMP/GDP Environments (PI 041-1 (Draft 2)) developed by the PIC/S Working Group on Data Integrity. This draft guidance will be applied on a 6-month trial basis by PIC/S Participating Authorities. This draft document results from the need among Inspectorates to have access to harmonised data integrity guidance, considering the impact to public health. The purpose of the trial-period is to learn from implementation. It is acknowledged that the guidance requires expanding in some areas; however, the document has value in describing foundational principles which can be enhanced in future revisions. This draft document is not open for comments by industry. Formal adoption of the guidance will proceed in accordance with PIC/S procedures – including a stakeholders’ consultation – on a revised version after completion of the trial-period.
As part of the new set of validation guidelines, including computer systems, WHO published a set of guidelines around this subject.
The CSV draft incorporates the data integrity elements as part of the system life cycle.
Current Warning Letter:
FDA found 8,400 unofficial chromatographic analyses at the Desano plant performed between 2012 and 2014. The company has acknowledged that some of those tests related to out-of-spec test results.
The FDA was also disturbed by finding many electronic logs of production deviations in a folder titled “GMP Anomalies” that had never been investigated.
Environmental Monitoring (EM) programs for pharmaceutical manufacturing are evolving to a risk-based approach. The use of sampling data for the identification and mitigation of risk becomes a critical element in this process. No longer is it enough to utilize data for reactive excursion reporting. The case study provided in this white paper highlights the need for automated EM software systems to analyze large amounts of data and recognize risks before a problem occurs.
NEW: WHO Expert Committee on specifications for pharmaceutical preparations (Fiftieth report) – WHO technical report series; no. 996 (Source)
including Annex 5 – Guidance on good data and record management practices – Download- including special risk management considerations for assuring accurate GXP records